Hoffmann-La Roche (Switzerland)

Swiss drug giant Roche has come under pressure on several sides in recent years, but generally for all the right reasons. Its pharmaceutical business remains very strong, with numerous new products ready for market, comparatively few facing imminent patent expiry and profits at record levels. This has occasionally led to the company being regarded as a takeover target, not least by Swiss rival Novartis which has steadily built up a shareholding of around 33% since 2000, despite Roche's objections. In order to focus more directly on its core business of drugs and diagnostics, Roche cut loose its consumer healthcare portfolio to Bayer in 2004. The group is a leader in in vitro diagnostics, as well as cancer and transplantation drugs.

Click here to access the Adbrands profile (subscribers only); or subscribe to Adbrands.net here. Adbrands Company Profiles provide a detailed analysis of the history and current operations of leading advertisers, agencies and brands worldwide, and include a critical summary which identifies key strengths and weaknesses. Adbrands Account Assignments tracks account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets..

Advertising: Which agencies handle advertising for Roche? The searchable account assignments database is available to full subscribers to Adbrands.net premium services. Click here for subscription information.

Competitors: see Pharmaceutical Sector index for other companies

Subscribers may access the following website links:

Roche website

Rituxan	Xeloda
Avastin	Tarceva
Igen	CellCept
Herceptin	Kytril
RoAccutane	Xenical
Pegasys	Tamiflu
Genentech	Chugai Pharmaceuticals
Roche Diagnostics	Accu-Chek

Roche worldwide

Click HERE to subscribe to Adbrands.net and access the profile and website links